ArticleThe journal of allergy and clinical immunology. In practice2021
SARS-CoV-2 Vaccines: Where Are We Now?
Article in The journal of allergy and clinical immunology. In practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiac MRI Findings in COVID-19 Vaccine-Related Myocarditis: A Pooled Analysis of 468 Patients.Journal of magnetic resonance imaging : JMRI · 2022Pooled it
- Autoantibodies to protein S may explain rare cases of coagulopathy following COVID-19 vaccination.Scientific reports · 2024Article
- Optimization and validation of a virus-like particle pseudotyped virus neutralization assay for SARS-CoV-2.MedComm · 2024Article
- COVID-19 vaccine uptake among young adults: Influence of asthma and sociodemographic factors.The journal of allergy and clinical immunology. Global · 2024Article
- Clinical, immunological, and microbiological analysis of the association between periodontitis and COVID-19: a case-control study.Odontology · 2024Article
- SARS-CoV-2 and thyroid diseases.Journal of translational autoimmunity · 2023Review
- Intelligent Health: Progress and Benefit of Artificial Intelligence in Sensing-Based Monitoring and Disease Diagnosis.Sensors (Basel, Switzerland) · 2023Review
- COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type.Viruses · 2023Article
- Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein.Vaccines · 2023Article
- Vaccine Acceptance During a Novel Student-led Emergency Department COVID-19 Vaccination Program.The western journal of emergency medicine · 2023Article
- Evaluating SARS-CoV-2 antibody reactivity to natural exposure and inactivated vaccination with peptide microarrays.Frontiers in immunology · 2023Article
- Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency.Genes · 2022Review
- Article
- Emerging trends of research on mRNA vaccines: A co-citation analysis.Human vaccines & immunotherapeutics · 2022Article
- Article
- Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2022Article
- COVID-19-Related Predictors of Fear and Attitude to Vaccination Displayed by Polish Students.Vaccines · 2022Article
- Lebanese SARS-CoV-2 genomics: 24 months of the pandemic.Virus research · 2022Article
- Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.Seminars in arthritis and rheumatism · 2022Observational
- In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by using vaccination to generate widespread immunity. The urgent need to develop safe and effective COVID-19 vaccines was met with unprecedented speed and action from the global community. There are now 289 vaccines in the development pipeline. More remarkably, there are 20 publicly available vaccines, and more than 3.3 billion doses of COVID-19 vaccines have been administered across 180 countries. This is just the beginning of our fight against the pandemic. Even at the current vaccination rate, it could take years to vaccinate the world's population; many high-income countries are focusing on their needs, whereas the poorer nations are waiting for vaccines. There is still much that we do not understand about immunity to this new disease, and we will have to contend with the emerging variants. In this commentary, we describe the current status of COVID-19 vaccine development and provide insights into how the development and approvals happened so quickly. We discuss the clinical trial data that led to rapid emergency use authorization and the many challenges of global rollout. We also comment on some of the key unanswered questions and future directions for COVID-19 vaccine development and deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.